Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immunovia AB (IMMNOV.ST)
SEK0.19
0.00 (-0.31%)
SE STO Healthcare Medical - Diagnostics & Research
Address
Medicon Village 223 63
Lund, SE
Lund, SE
CEO
Jeff Borcherding
Website
immunovia.com
IPO
2015-12-01
ISIN SE0006091997
Also trades on
London Stock Exchange · 0G8X.L (SEK)
Other OTC · IMMVF (USD)
Stockholm Stock Exchange · IMMNOV.ST (SEK)
Description
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK0.19
0.00 (-0.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
2.68
Float Shares
332.33M
Free Float %
97.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.31% | +4.76% | -9.11% | +7.56% | -35.47% | -14.71% | -35.49% | -85.22% | -99.50% | -99.06% | -98.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.19
DCF (Unlevered)
0.22
+11.3%
DCF (Levered)
0.22
+13.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-28.80
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-26.4% Q1'26: +169.1% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+54.8% ★ Q1'26: +88.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-20,535.8% Q1'26: -5,586.4% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-11,606.4% Q1'26: -4,724.1% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%— Q1'26: +776.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+316.8% Q1'26: +178.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
177.3K
est: 200.0K (-11.4%)
|
149.0K
est: 27.80M (-99.5%)
|
332.6K
est: 333.0K (-0.1%)
|
356.0K
est: 300.0K (+18.7%)
|
844.0K
est: 2.45M (-65.6%)
|
1.15M
est: 1.00M (+14.5%)
|
1.58M
est: 69.00M (-97.7%)
|
931.0K
est: 622.00M (-99.9%)
|
685.0K
est: 1.00M (-31.5%)
|
4.40M
4.40M – 4.40M
+340.0% YoY
|
22.60M
22.60M – 22.60M
+413.6% YoY
|
54.00M
54.00M – 54.00M
+138.9% YoY
|
109.00M
109.00M – 109.00M
+101.9% YoY
|
| EBITDA |
-14.20M
est: -200.0K (-6,999.6%)
|
-43.97M
est: -27.80M (-58.1%)
|
-83.75M
est: -333.0K (-25,051.3%)
|
-104.75M
est: -300.0K (-34,817.3%)
|
-135.47M
est: -2.45M (-5,429.4%)
|
-141.58M
est: -1.00M (-14,057.9%)
|
-166.56M
est: -69.00M (-141.4%)
|
-61.27M
est: -622.00M (+90.2%)
|
-77.18M
est: -1.00M (-7,617.9%)
|
-4.40M
-4.40M – -4.40M
-340.0% YoY
|
-22.60M
-22.60M – -22.60M
-413.6% YoY
|
-54.00M
-54.00M – -54.00M
-138.9% YoY
|
-109.00M
-109.00M – -109.00M
-101.9% YoY
|
| EBIT |
-14.72M
est: -200.0K (-7,261.6%)
|
-45.22M
est: -27.80M (-62.7%)
|
-86.53M
est: -333.0K (-25,885.4%)
|
-113.20M
est: -300.0K (-37,633.0%)
|
-154.53M
est: -2.45M (-6,207.5%)
|
-166.49M
est: -1.00M (-16,549.2%)
|
-308.28M
est: -69.00M (-346.8%)
|
-74.68M
est: -622.00M (+88.0%)
|
-79.50M
est: -1.00M (-7,850.4%)
|
-4.40M
-4.40M – -4.40M
-340.0% YoY
|
-22.60M
-22.60M – -22.60M
-413.6% YoY
|
-54.00M
-54.00M – -54.00M
-138.9% YoY
|
-109.00M
-109.00M – -109.00M
-101.9% YoY
|
| Net Income |
-14.72M
est: -20.43M (+27.9%)
|
-45.23M
est: -30.80M (-46.9%)
|
-86.54M
est: -138.30M (+37.4%)
|
-114.52M
est: -134.15M (+14.6%)
|
-157.40M
est: -207.30M (+24.1%)
|
-145.03M
est: -199.01M (+27.1%)
|
-309.44M
est: -258.24M (-19.8%)
|
-76.54M
est: 930.67M (-108.2%)
|
-145.92M
est: -185.94M (+21.5%)
|
-44.76M
-44.76M – -44.76M
+75.9% YoY
|
-20.66M
-20.66M – -20.66M
+53.8% YoY
|
-10.33M
-10.33M – -10.33M
+50.0% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
24.12M
est: 14.86M (+62.3%)
|
39.11M
est: 2.07B (-98.1%)
|
65.28M
est: 24.74M (+163.9%)
|
78.32M
est: 22.29M (+251.4%)
|
82.61M
est: 182.00M (-54.6%)
|
-47.90M
est: 74.29M (-164.5%)
|
148.30M
est: 5.13B (-97.1%)
|
-28.45M
est: 14.88B (-100.2%)
|
—
est: 23.93M (-100.0%)
|
105.28M
105.28M – 105.28M
+340.0% YoY
|
540.78M
540.78M – 540.78M
+413.6% YoY
|
1.29B
1.29B – 1.29B
+138.9% YoY
|
2.61B
2.61B – 2.61B
+101.9% YoY
|
| EPS |
-0.91
est: -0.25 (-267.9%)
|
-2.48
est: -0.37 (-565.2%)
|
-4.33
est: -1.67 (-158.7%)
|
-5.43
est: -1.62 (-234.4%)
|
-6.45
est: -2.51 (-157.0%)
|
-5.95
est: -2.41 (-147.0%)
|
-7.95
est: -3.13 (-154.3%)
|
-0.93
est: 2.70 (-134.4%)
|
-0.42
est: -0.54 (+22.2%)
|
-0.13
-0.13 – -0.13
+75.9% YoY
|
-0.06
-0.06 – -0.06
+53.8% YoY
|
-0.03
-0.03 – -0.03
+50.0% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-80.30M
OE per share TTM
-0.19
Owner's Yield
-61.86%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3,668.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-61.2K
Shares Outstanding
342.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeff Borcherding | Global Chief Executive Officer & President | 7M | male |
| Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMMNOV.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
